- Home
- SENEB vs VERA Comparison
SENEB vs VERA Comparison
Compare SENEB & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEB | VERA |
|---|---|---|
| Founded | 1949 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 813.0M | 1.5B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SENEB | VERA |
|---|---|---|
| Price | $110.27 | $49.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $76.60 |
| AVG Volume (30 Days) | 380.0 | ★ 1.3M |
| Earning Date | 02-05-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.79 | N/A |
| EPS | ★ 8.61 | N/A |
| Revenue | ★ $1,606,175,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.83 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $71.47 | $18.53 |
| 52 Week High | $124.94 | $56.05 |
Technical Indicators
Market Signals| Indicator | SENEB | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 56.78 |
| Support Level | $109.56 | $45.02 |
| Resistance Level | $115.00 | $49.28 |
| Average True Range (ATR) | 0.39 | 2.32 |
| MACD | -1.65 | -1.03 |
| Stochastic Oscillator | 9.78 | 36.45 |
Price Performance
Historical ComparisonAbout SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.